Completed OBSERVATIONAL NCT02623257

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer

Sponsor: First People's Hospital of Hangzhou

Conditions Non-Small-Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage III

Interventions ARMS ctDNA analysis mutation detection

Updated 7 times since 2017 Last updated: Feb 12, 2018 Started: Jan 31, 2016 Primary completion: Jul 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Non-Small-Cell Lung Cancer Metastatic and Non-small Cell Lung Cancer Stage III and is currently completed. First People's Hospital of Hangzhou leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Mar 2018 — Apr 2018 [monthly]

Completed NA

Status: Recruiting → Completed
Jan 2017 — Mar 2018 [monthly]

Recruiting NA

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First People's Hospital of Hangzhou

Data source: First People's Hospital of Hangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China